Disclosures: Eunho Choi: Nothing to Disclose, Young-Sun Lee: Nothing to Disclose, Jeong-An Gim: Nothing to Disclose, Wonhyo Seo: Nothing to Disclose, Ha Seok Lee: Nothing to Disclose, Youngwoo Lee: Nothing to Disclose, Yang Jae Yoo: Nothing to Disclose, Seong Hee Kang: Nothing to Disclose, Sun Young Yim: Nothing to Disclose, Young Kul Jung: Nothing to Disclose, Ji Hoon Kim: Nothing to Disclose, Yeon Seok Seo: Nothing to Disclose, Hyung Joon Yim: Nothing to Disclose, Jong Eun Yeon: Nothing to Disclose, Kwan Soo Byun: Nothing to Disclose 1915 THE COMPOSITION OF CIRCULATING IMMUNE CELLS FOLLOWING TREATMENT WITH ATEZOLIZUMAB AND BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA Eunho Choi 1 Ha Seok Lee 1 Young-Sun Lee 1 Youngwoo Lee 1 Yang Jae Yoo 1 Seong Hee Kang 1 Sun Young Yim 1 Young Kul Jung 1 Ji Hoon Kim 1 Yeon Seok Seo 1 Hyung Joon Yim 1 Jong Eun Yeon 1 Kwan Soo Byun 1 , 1 Korea University College of Medicine Background: Currently, combination therapy of atezolizumab and bevacizumab is used as a first-line therapy for advanced hepatocellular carcinoma
People with lipedema often have excess fat buildup, particularly in the legs and arms
The gentle formula soothes skin redness and leaves the skin feeling soft despite any dryness that may be occurring
Besides soluble factors, CAFs exert immunosuppressive effects by modulating cellcell interactions and the physical tumor matrix
